JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Geschlossen

BrancheGesundheitswesen

13.8

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.77

Max

13.86

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.8B

14B

Verkäufe

392M

85B

KGV

Branchendurchschnitt

17.909

34.393

Dividendenrendite

0.66

Gewinnspanne

16.496

Angestellte

27,811

EBITDA

-622M

25B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+17.39% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.66%

2.54%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-476M

12B

Vorheriger Eröffnungskurs

13.8

Vorheriger Schlusskurs

13.8

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Juli 2025, 17:49 UTC

Ergebnisse

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23. Juli 2025, 17:48 UTC

Ergebnisse

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23. Juli 2025, 17:48 UTC

Ergebnisse

Dr Reddy's Labs 1Q Rev $85.45B >RDY

9. Mai 2025, 18:56 UTC

Ergebnisse

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

9. Mai 2025, 18:56 UTC

Ergebnisse

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

23. Jan. 2025, 17:46 UTC

Ergebnisse

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23. Jan. 2025, 17:42 UTC

Ergebnisse

Dr. Reddy's 3Q Rev INR83.59B

5. Nov. 2024, 11:01 UTC

Ergebnisse

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5. Nov. 2024, 11:00 UTC

Ergebnisse

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5. Nov. 2024, 10:57 UTC

Ergebnisse

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5. Nov. 2024, 10:57 UTC

Ergebnisse

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

Peer-Vergleich

Kursveränderung

Dr Reddy's Laboratories Ltd-ADR Prognose

Kursziel

By TipRanks

17.39% Vorteil

12-Monats-Prognose

Durchschnitt 16.2 USD  17.39%

Hoch 16.9 USD

Tief 15.5 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Dr Reddy's Laboratories Ltd-ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 13.84Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.